Kornimate/medical-research-clean huggingface dataset:
potassium supplementation to reduce blood pressure

Conditions: Prehypertension

Summary: the aim of this study is to conduct a definitive trial to assess the efficacy of consuming 1l/day of water rich in potassium to reduce blood pressure in mild to moderately hypertensive adults. the objective is to assess the potential effect of the intervention on reducing systolic blood pressure. this study will comprise of a 4 week, double-blind, parallel randomised controlled trial. participants will be adults with systolic blood pressure measurements of 130mmhg or greater. the intervention comprises advice to consume bottled water rich in potassium. the comparator will be regular bottled mineral water.this study will recruit 40 people with elevated systolic blood pressure (≥130mmhg) who are not regularly taking antihypertensive medication.


Eligibility criteria:
inclusion criteria: * willing and able to provide informed consent * between 20 to 64 years old * english speaking * adults who are not receiving antihypertensive pharmacological treatment * recent (within 6 months) and latest systolic blood pressure measurement ≥130mmhg and/or diastolic ≥85 mmhg * have access to internet and equipment for video calling * able to post samples and equipment to oxbcnh * physically able to take own body measurements and blood pressure exclusion criteria: * participation in another research study * unable to read and understand the instructions provided in english * unable to comply with experimental procedures or not follow testing safety guidelines * people with cardiovascular conditions: heart attack or stroke within the last 3 months, heart failure of grade ii new york heart association and more severe, or prolonged qt syndrome, angina, arrhythmia or atrial fibrillation. * uncontrolled type 2 diabetes (hba1c\> 9%) * type 2 diabetes controlled using exogenous insulin * previous or current diagnosis of diabetes complications such as nephropathy, retinopathy and neuropathy. * people with type 1 diabetes * currently on any medication that may lead to hyperkalemia or fluid retention * currently being assessed for diagnosis of hypertension (not receiving treatment for high blood pressure) * already on clinician/hcp supervised diet or restricted diet * they are planning on going away from home (holiday or other) during the 4 week intervention period and will not be able to take water during this time. * currently prescribed antihypertensive medications, or have been in the last 6 weeks * chronic kidney disease stage 1 (g1a2 or g1a3), 2 (g2a2 or g2a3), 3a, 3b, 4 or 5 based on ukka (we will ask whether participants have been diagnosed with kidney disease by a clinician based on this criteria) * they are planning to go on a diet or begin taking supplements containing potassium during the intervention * pregnant women (including women suspected of being pregnant) and breast-feeding woman.

Keywords: potassium blood pressure systolic randomised
study of tipifarnib in patients with high-risk myelodysplastic syndrome (mds)

Conditions: Myelodysplastic Syndrome

Summary: the purpose of this study is to characterize the hematological response rate, as well as other parameters of efficacy and safety induced by tipifarnib in patients with high-risk myelodysplastic syndrome (mds). tipifarnib belongs to a class of drugs called farnesyl transferase inhibitors (fti). it blocks proteins that make cancer cells grow.

treatment with tipifarnib will be given during one or more periods of time called cycle(s). each cycle will be 28 days long and patients will take tipifarnib for the first 21 days of each cycle. no medication will be taken during the last 7 days of each cycle. on day 1 and 15 of each cycle, patients will be asked about any side effects that have occurred since their last visit. blood will drawn for routine testing to evaluate any possible effects of tipifarnib on white blood cells or on specific elements, that can be measured in the blood. the study doctor will decide if any bone marrow aspirates or biopsies should be taken. tipifarnib will be given until the patient's disease worsens or they develop unacceptable side effects or until they withdraw consent to receive tipifarnib. when tipifarnib treatment is ended or if the patient leaves the study early, they will be asked to come in for a final visit. the study doctor will decide if any blood draws, bone marrow aspirates or biopsies need to be taken. tipifarnib is 300 mg administered orally as three 100 mg tablets twice daily for the first 21 days in each 28-day cycle. tipifarnib will be administered until the patient discontinues treatment due to disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * pathological evidence of mds * not more than 1 prior cytotoxic treatment for mds * able to take oral study drug * able to understand and provide signed informed consent exclusion criteria: * refractory anemia (ra) or ra with excess of blasts (raeb) or patients with raeb with \< or = 10% marrow blasts * treatment-related mds, if treated with chemotherapy less than 3 years ago * not adequately recovered from any treatment-related non-hematological toxicity * refractory to platelet transfusion * candidates for hematopoietic stem cell transplantation * previous therapy with a farnesyl transferase inhibitor * prior extensive radiation therapy

Keywords: r115777 myelodysplastic syndromes tipifarnib zarnestra
atorvastatin in management of newly diagnosed itp

Conditions: Immune Thrombocytopenia; Purpura, Thrombocytopenic

Summary: the project was undertaking by qilu hospital of shandong university in china. in order to report the efficacy and safety of atorvastatin for the treatment of adults with immune thrombocytopenia (itp).

the investigators anticipate to undertaking a parallel group, single-centre, randomised controlled trial of 30 itp adult patients, which have no indications of glucocorticoid therapy (platelets count \> 30\*10\^9/l )from qilu hospital of shandong university in china.15 of the participants are randomly selected to receive atorvastatin in 20 mg/d combining with 10 mg/d for 6 months. platelet count, bleeding and other symptoms were evaluated before and after treatment, adverse events are also recorded throughout the study in order to report the efficacy and safety of atorvastatin for the treatment of adults with itp.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria for immune thrombocytopenia. 2. within 3 months from diagnosis,untreated patients, may be male orfemale, between the ages of 18 \~ 80 years. 3. to show a platelet count \> 30×10\^9/l and without bleeding manifestations. exclusion criteria: 1. received chemotherapy or anticoagulants or other drugs affecting theplatelet counts within 3 months before the screening visit. 2. received steroids or other effective therapy for immune thrombocytopenia. 3. current hiv infection or hepatitis b virus or hepatitis c virus infections. 4. severe medical condition (lung, hepatic or renal disorder) other than itp. 5. unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) 6. female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period. 7. have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct coombs test. 8. patients who are deemed unsuitable for the study by the investigator.

Keywords: immune thrombocytopenia
relationship between pelvic tilt and sit to stand task in stroke patients

Conditions: Stroke

Summary: the purpose of this study is to assess and determine the influence of pelvic inclination on sit to stand task in stroke patients.

there is a crucial need to have a better understanding of effect of pelvic inclination on sit to stand activity and to know the important factors to be considered to improve the patients' treatment and performance. forty five participants are recruiting to assess the pelvic tilt angles in stroke patients during sitting position and to analyze the influence of pelvic tilt angles on ability to perform sit to stand task during rising from a chair in stroke patients.

Eligibility criteria:
inclusion criteria: * patients' age ranged from 45-60 years old. * normal body weight with a body mass index (bmi) ranged from 18.5 to 24.9 kg/m2. * patients' had the ability to maintain sitting position without using any aids. * patients' had the ability to stand from sitting five times independently. * cooperative patients with ability to understand instructions and follow simple verbal commands. * the duration of illness was from six months to 2 years. * the degree of the paretic lower limb spasticity ranged between (1:1+) according to the modified ashworth scale. * the degree of the paretic lower limb weakness was not less than grade 3 according to group muscle testing. exclusion criteria: * history of previous strokes and other neurological disorders. * visual, auditory and vestibular deficits. * cognitive impairments and language deficits. * leg length discrepancy is more than 0.5 cm. * previous history of orthopedic conditions in back or lower limbs (e.g. low back pain, fractures, deformities and surgeries).

Keywords: pelvic inclination sit to stand stroke anterior pelvic tilt posterior pelvic tilt
clonidine-remifentanil. effect of the combination on acute pain and respiration in healthy volunteers

Conditions: Acute Pain; Respiration; Sedation

Summary: the hypothesis is that systemic remifentanil and clonidine act in a synergistic manner to relief acute main in an experimental human pain model. of interest is also the effect of the combination on respiration, sedation and cognitive behavior.

to examine the possible synergistic effects og systemic remifentanil and clonidine. its effects on respiration, cognitive function and sedation.

Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: -

Keywords: remifentanil clonidine acute pain respiration sedation cognitive function
efficacy and safety study of peg-ril-29 plus ribavirin to treat chronic hepatitis c virus infection

Conditions: Hepatitis C, Chronic

Summary: interleukin 29 (il-29) is a substance that is produced in the body to help fight viral infections. the purpose of this study is to evaluate the safety and antiviral effects of several different doses of peg-ril-29 (a man-made form of il-29) when it is given in combination with daily oral doses of ribavirin (an antiviral drug) to subjects with hepatitis c infection who have received no prior treatment for this disease.

peg-ril-29 (also known as peg-interferon lambda) is a unique type iii interferon molecule that has demonstrated antiviral activity when administered weekly for 4 weeks to treatment-relapsed and treatment-naive subjects with genotype 1 hepatitis c virus (hcv) infection. because peg-ril-29 binds to a unique receptor with a more limited distribution than the receptor for interferon (ifn)-α, it may have the potential to treat hcv without some of the treatment-limiting side effects associated with ifn-α-based therapies. the purpose of this phase 2a/b randomized, controlled, multicenter study is to compare the safety and efficacy of peg-ril-29 and peginterferon alfa-2a, both administered subcutaneously weekly for up to 48 weeks in combination with daily oral ribavirin, in treatment-naive subjects with chronic genotype 1, 2, 3, or 4 hcv infection. the initial part of the study (phase 2a) will be conducted as an open-label study; the second part of the study (phase 2b) will be conducted as a blinded study. the above information provided in this listing is specific to the phase 2b portion of the study. in addition, two small open-label substudies will be conducted to evaluate the efficacy of 24-week treatment with peg-ril-29 and ribavirin in subjects with hcv genotype 1 who have a particular genetic polymorphism associated with favorable response (n=60) and to evaluate the efficacy of 16-week treatment with peg-ril-29 and ribavirin in subjects with hcv genotype 2 or 3 (n=30).

Eligibility criteria:
inclusion criteria: * no prior therapy for chronic hcv, other than up to 2 weeks of single-agent therapy with a direct-acting antiviral agent, including but not limited to, a protease or polymerase inhibitor * hcv genotype 1, 2, 3, or 4 * hcv rna ≥100,000 iu/ml * alt and ast ≤5.0 × uln * documented absence of cirrhosis * able to comprehend the investigational nature of this study and sign an informed consent form exclusion criteria: * mixed genotype hcv infection * current or prior history of decompensated liver disease * received any investigational drug, including a direct-acting antiviral agent, within 60 days prior to receiving study drug * positive test for hepatitis b surface antigen, human immunodeficiency virus (hiv)-1, or hiv2 antibody at screening * active substance abuse, such as alcohol, or inhaled or injected drugs, within 6 months additional inclusion and exclusion criteria are specified in the protocol.

Keywords: hepatitis c hepatitis c, chronic pegylated recombinant interleukin 29 peg-interferon lambda interleukin 29 virus infection liver diseases
the effect of supplemental docosahexaenoic acid (dha) on neurocognitive outcomes in teen and adult women with phenylketonuria(pku)

Conditions: Phenylketonuria

Summary: the purpose of this study is to determine if taking supplemental dha improves measures of processing speed and executive function in teen and adult women with pku.


Eligibility criteria:
inclusion criteria: * females * phenylketonuria * ages 12 years and older * able to complete neuropsychological testing exclusion criteria: * pregnancy * currently taking dha supplement

Keywords: phenylketonurias docosahexaenoic acids neuropsychological tests female adolescent adult
effect of muscular imbalance between flexors and extensors of the fingers and wrist on upper limb injuries in climbers

Conditions: Climber

Summary: climbing is a booming sport with an increasing number of participants. when practicing this sport, there is a muscular imbalance between the flexor and extensor systems (especially in the fingers), with the flexors of the fingers exerting greater force than the extensors. in addition, upper limb injuries, particularly the fingers, are very common. the study will be carried out on club-licensed climbers, as they are better supervised. they will be recruited through requests sent to various clubs. the measurements will be taken during different climbing sessions, after the warm-up. the study will include measurements on different climbers. informed consent and personal data will be collected from the climbers before the measurements are taken. the strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer. the climbers will then continue their usual training for 1 year. for 1 year after the measurements, the climbers will be contacted every month by telephone to collect the different injuries they may have suffered in relation to climbing, as well as the number of hours they have spent climbing in the past month. after 1 year, the annual number of hours of climbing and the annual number of injuries can be calculated for each climber. injury is defined as any medically diagnosed lesion of the musculoskeletal system of the upper limb or pain that prevents the practice of a sport whose aetiology is climbing. these data are used to calculate the "athlete exposure" (a-e), i.e. the incidence of injury per 1000 hours of practice. as the study population is large, this allows for variations in exposure between subjects.


Eligibility criteria:
* a male or female climber who has been a member of a climbing club for at least 1 year; * have a level of 6a "on sight" or higher; * fluent in spoken and written french; * over 18 years of age. exclusion criteria: * declaration of a medically diagnosed upper limb injury at the time of testing; * presence of any pathology that prevents climbing or taking finger or wrist measurements; * volunteers for whom it is impossible to collect data by telephone.
awareness, expectations, and perception of anomaly scan among mexican pregnant women

Conditions: Knowledge; Expectations; Ultrasound

Summary: to describe the knowledge, expectations, and perception of women towards the mid-trimester ultrasound scan to detect fetal anomalies in a mexican population.

a cross-sectional survey was conducted in two prenatal diagnostic centers located in monterrey, nuevo león, méxico. one was a university prenatal diagnostic center and the other a private one. the centers were purposively selected to represent different characteristics of the level of care and demographic characteristics. the research instrument was a 26-item questionnaire divided into three sections. the first section contained 12 questions designed to assess women's ideas about the purpose and limitations of the scan (yes/no). the second was on expectations before the scan while the third dealt on women´s perception of the fetus during the ultrasound examination. all women attending for a mid-trimester anomaly scan were invited to fill out the first two parts of a pretested structured questionnaire before the scan and after the ultrasound examination, the third part of the questionnaire concerning their experience of the scan session was completed and collected. additionally, the questionnaire included demographic questions (age, parity, educational level, marital status). the source of the questionnaire items was interviews with experts. ethical approval for this study was obtained from the institutional review board. the anomaly scan was performed by fetal-maternal specialists between 18 and 24.6-week gestation. all data were recorded and analyzed using the statistical package for the social sciences version 22.0 (spss inc, illinois, usa). descriptive statistics were used for the sociodemographic data. categorical variables were compared using the chi-square test or fisher exact test. univariate and multivariate regression analyses were performed to delineate the factors associated with a higher knowledge level. a p-value \<0.05 was considered statistically significant.

Eligibility criteria:
inclusion criteria: -pregnant women between 18 and 24.6 weeks exclusion crireria: * time constraints * lack of interest * maternal blindness

Keywords: knowledge expectations anomaly scan
international penile advanced cancer trial (international rare cancers initiative study)

Conditions: Squamous Cell Carcinoma of the Penis, Usual Type

Summary: this is an international phase iii trial, with a bayesian design, incorporating two sequential randomisations. it efficiently examines a series of questions that routinely arise in the sequencing of treatment. the study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. it will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provide data to inform future clinical decisions. inpact-neoadjuvant patients are stratified by disease burden as assessed by radiological criteria. treatment options are then defined according to the disease burden strata. treatment is allocated by randomisation. patients may be allocated to one of three initial treatments: a. standard surgery (ilnd); b. neoadjuvant chemotherapy followed by standard surgery (ilnd); or c. neoadjuvant chemoradiotherapy followed by standard surgery (ilnd). after ilnd, patients are defined as being at low or high risk of recurrence based on histological interpretation of the ilnd specimen. patients at high risk of relapse are eligible for inpact-pelvis, where they are randomised to either: p. prophylactic plnd q. no prophylactic plnd


Eligibility criteria:
inclusion criteria: 1. written informed consent 2. measurable disease as determined by recist (version 1.1) criteria; 3. histologically-proven squamous cell carcinoma of the penis, 4. stage: * any t, n1 (i.e. a palpable mobile unilateral inguinal lymph node), m0 or; * any t, n2 (i.e. palpable mobile multiple or bilateral inguinal lymph nodes), m0 or; * any t, n3 (i.e. fixed inguinal nodal mass or any pelvic lymphadenopathy), m0 5. performance status ecog 0, 1 or 2. exclusion criteria: 1. pure verrucous carcinoma of the penis, 2. nonsquamous malignancy of the penis, 3. squamous carcinoma of the urethra, 4. stage m1, 5. previous chemotherapy or chemoradiotherapy, 6. concurrent malignancy (other than scc or basal cell carcinoma of non-penile skin) that has required surgical or non-surgical treatment in the last 3 years.

Keywords: penis cancer chemotherapy chemoradiotherapy surgery phase iii
personalized mood augmentation trial for depressed mood

Conditions: Depression

Summary: the goal of this open-label single-arm study is to test personalized behavioral intervention for depressed mood.

the goal of this open-label single-arm study is to test personalized behavioral intervention for depressed mood. after an initial period (2-4 weeks) of mood and lifestyle monitoring using smartphone and smartwatch data, participants will be assigned to an evidenced-based behavioral plan that target their lifestyle for 6 weeks. the trial will evaluate changes in depressed mood, associated health behaviors and cognition.

Eligibility criteria:
inclusion criteria: * mild to moderate depression per phq9 symptom ratings exclusion criteria: * active substance abuse/dependence * psychotic disorders * bipolar disorder * eating disorder * displaying acutely suicidal behaviors